CompletedPhase 2NCT00570661

Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis

Studying Juvenile idiopathic arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Italfarmaco
Principal Investigator
Nemanja Damjanov, MD, PhD
Institute of Rheumatology Belgrade
Intervention
ITF2357(drug)
Enrollment
17 enrolled
Eligibility
2-25 years · All sexes
Timeline
20062013

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00570661 on ClinicalTrials.gov

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile idiopathic arthritis

← Back to all trials